A Patient Survey to Identify Atopic Dermatitis Prescription Treatment Access Barriers

Allison R. Loiselle, PhD1, Isabelle J. Thibau, MPH1, Michele Guadalupe, MPH1,
Lisa Butler, MBA1, Wendy Smith Begolka, MBS1

1National Eczema Association, Novato, CA, USA

Presented at the American Academy of Dermatology 2022 Annual Meeting
Boston, MA
March 25-29, 2022
Background and Objectives

- Atopic dermatitis (AD) is the most prevalent form of eczema and is a chronic disease with a relapsing-remitting nature.
- Multiple treatment options exist, yet little is known about patients' ability to obtain recommended prescription treatments.

Objective 1:
Determine frequency/causes of insurance delays and denials for AD prescription treatments.

Objective 2:
Determine the impact of AD prescription delays and denials on patient quality of life.

Methods

- 71 question voluntary online survey.
- Inclusion criteria (US residents age ≥18 years; self-report of AD or primary caregivers of children with AD) was met by 96.7% (1,272/1,315) of respondents.
- Survey areas included:
  - sociodemographic factors
  - AD current prescription use and treatment history
  - experiences with coverage delays and denials
  - impact of those delays and denials
  - navigating insurance

Funding and Disclosures: Funding support for this work was provided by the National Eczema Association (NEA). ARL, IJT, MG, LB, and WSB are salaried employees of NEA. WSB has also served as an advisory board member and/or investigator for Incyte and Pfizer.
## Results

**Total AD prescriptions used by patients currently or in the past 12 months**

<table>
<thead>
<tr>
<th>Currently using</th>
<th>Steroids (topical)</th>
<th>Steroids (oral/injectable)</th>
<th>Topicals</th>
<th>Orals</th>
<th>Injectable (biologics)</th>
<th>Total Prescriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>47.6% (n=1,189)</td>
<td>7.2% (n=179)</td>
<td>23.9%</td>
<td>12.7%</td>
<td>8.5%</td>
<td>2,497</td>
</tr>
<tr>
<td>Not using currently, but used in past 12 months</td>
<td>34.3% (n=1,000)</td>
<td>13.7% (n=399)</td>
<td>25.5%</td>
<td>21.7%</td>
<td>4.8%</td>
<td>2,915</td>
</tr>
</tbody>
</table>

50% of patients experienced at least one delay or denial in the past 12 months (n=1,272)

68% were aware they could appeal an insurer's decision to deny coverage

73.7% who identified as white were aware

57.3% who identified as non-white were aware
Results, cont.

Reason for delays

- Mail order service delays: 11.3%
- Prior authorization: 60.2%
- Other issue: 10.0%
- I don't know: 18.5%

(n=432)

Wait time for medication due to delay (n=365)

- Within 3 days
- 4-7 days
- 8 days-2 weeks
- 3-4 weeks
- 5 weeks-3 months
- 4 months or more

Proportion (%)

Time to appeal a coverage denial (n=330)

- Within 3 days
- 4-7 days
- 8 days-2 weeks
- 3-4 weeks
- 5 weeks-3 months
- 4 months or more

Proportion (%)

- Steroids
- Topicals
- Orals
- Injectables

Reason for denials

- Step therapy: 50.3%
- Insurer removed from list of covered drugs: 13.9%
- Changed insurers and drug was no longer covered: 13.7%
- I don't know: 16.2%
- Other issue: 5.9%

(n=710)
Patients with AD and their families frequently experience issues obtaining recommended therapies which can result in detrimental health and quality of life impacts. These data may help identify strategies to improve timely and beneficial therapeutic access.